China's NEO Brain Chip Becomes First Invasive BCI Approved for Widespread Patient Use
Key Takeaways
- ▸Neuracle Technology's NEO is the first invasive brain-computer interface approved for use beyond clinical trials, marking a major milestone in neurotechnology commercialization
- ▸The device enables paralyzed spinal cord patients to regain voluntary limb movement by translating brain signals into actionable motor commands
- ▸NEO's less-invasive design—operating on the brain's surface rather than penetrating brain tissue—contributed to faster regulatory approval and lower medical risks
Summary
In March 2025, Neuracle Technology's NEO brain-computer interface became the first invasive BCI product approved for use beyond clinical trials anywhere in the world. Developed in partnership with researchers at Tsinghua University in Beijing, the coin-sized device sits on the brain's protective outer membrane and translates neural signals into movement commands. Patient Dong Hui, paralyzed from the neck down after a spinal cord injury six years earlier, began using NEO in November 2024 and regained the ability to write and perform fine motor tasks after 11 months of rehabilitation.
The NEO implant places sensors on the dura mater (the brain's protective outer layer), with an additional implant on the skull transmitting signals to a computer. During daily training sessions, users wear a soft robotic glove to learn motor control. Dong Hui's progress exemplifies the device's potential: by day nine of training, he could grab a ball without the glove—a moment he called miraculous.
Neuracle's rapid regulatory approval likely stems from NEO's less-invasive design compared to competitors. Unlike Neuralink's N1 chip, which directly penetrates the brain's cortex, NEO sits atop the protective membrane, significantly reducing risks of hemorrhage, scarring, and long-term signal degradation. China's expedited regulatory pathway, combined with NEO's established safety profile from 36 clinical trials, positioned the device for this historic milestone. The approval now makes NEO available to patients aged 18-60 with complete limb paralysis from spinal cord injuries.
- China's rapid approval reflects the country's strategic investment in neurotechnology and competitive positioning against U.S.-based competitors like Neuralink
Editorial Opinion
Neuracle's NEO represents a genuine inflection point in neurotechnology: proof that invasive brain-computer interfaces can achieve clinical efficacy and regulatory approval without requiring extensive long-term safety data. The device's surface-based approach suggests a middle path between caution and innovation, potentially making BCI technology more accessible globally. However, this approval also underscores an emerging reality—China's willingness to move quickly on high-risk medical devices may reshape regulatory standards and investment flows in neurotechnology worldwide.
